SCHEMBL3013157

SCHEMBL3013157

Cc1ccc(Cc2csc(N3CCC(S(=O)(=O)c4cc(Cl)ccc4Cl)CC3)n2)cc1C

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.36
NPSR1 Q6W5P4 3/20 0.36
LMNA P02545 2/20 0.36
TSHR P16473 3/20 0.35
HTT P42858 2/20 0.35
CNR1 P21554 2/20 0.35
MEN1 O00255 1/20 0.35
POLB P06746 1/20 0.35
KMT2A Q03164 1/20 0.35
CNR2 P34972 1/20 0.35
ALDH1A1 P00352 2/20 0.34
GAA P10253 2/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
KDM4E B2RXH2 1/20 0.34
RECQL P46063 1/20 0.34
TP53 P04637 2/20 0.33
ALOX15 P16050 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
PPARG P37231 1/20 0.33
PPARD Q03181 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3007899 0.93 GAA (0.35) MAPTNPSR1LMNAHTTCNR1
SCHEMBL3011591 0.91 ACHE (0.36) MAPTNPSR1LMNATSHRHTT
SCHEMBL3011255 0.91 MAPT (0.37) MAPTNPSR1LMNATSHRHTT
SCHEMBL3012479 0.91 MAPT (0.39) MAPTNPSR1LMNATSHRHTT
SCHEMBL3005119 0.90 CTSS (0.40) LMNACNR1MEN1KMT2ACNR2
SCHEMBL3001757 0.90 CNR1 (0.35) LMNACNR1MEN1KMT2ACNR2
SCHEMBL3016811 0.90 MAPK1 (0.38) MAPTNPSR1LMNATSHRHTT
SCHEMBL3021640 0.89 ACHE (0.36) MAPTNPSR1LMNATSHRHTT
SCHEMBL3017811 0.89 TSHR (0.36) MAPTNPSR1TSHRHTTCNR1
SCHEMBL3006085 0.89 GAA (0.38) MAPTNPSR1LMNATSHRHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA MAPT 18/4885NPSR1 764/4885LMNA 80/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.